Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
Conditions: ICB-refractory Melanoma Interventions: Other: Prebiotic Food-Enriched Diet; Drug: Ipilimumab; Drug: Nivolumab Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
Conditions: BRAF-positive Metastatic Melanoma Sponsors: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
Conditions: Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma Interventions: Drug: SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection; Drug: Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Radiation: Hyperfractionated radiotherpy; Radiation: Control group Sponsors: Lund University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
ctDNA for Early Detection of Recurrence in Melanoma
Conditions: Melanoma Sponsors: Herlev and Gentofte Hospital; Danish Cancer Society; Danish Cancer Research Foundation; DCCC ctDNA Research Center; CAG in Cancer immunotherapy Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
Conditions: Melanoma Interventions: Drug: fianlimab; Drug: cemiplimab; Drug: relatlimab+nivolumab Sponsors: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Conditions: Uveal Melanoma Interventions: Drug: Tebentafusp Sponsors: European Organisation for Research and Treatment of Cancer - EORTC; Northwell Health Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma Interventions: Drug: Sintilimab; Drug: Placebo Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Other: non-intervention Sponsors: Tianjin Medical University Cancer Institute and Hospital; Chinese Academy of Medical Sciences; Sichuan Cancer Hospital and Research Institute Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Other: no-Intervention Sponsors: Tianjin Medical University Cancer Institute and Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
A Study of MGC026 in Participants With Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer Interventions: Biological: MGC026 Dose Escalation; Biological: MGC026 Dose for Expansion Sponsors: MacroGenics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Conditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma Interventions: Biological: PD-L1 t-haNK; Drug: Cetuximab; Biological: N-803 Sponsors: Glenn J. Hanna; ImmunityBio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Conditions: Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer Interventions: Drug: LY4101174 Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Conditions: Melanoma Interventions: Drug: Ipilimumab; Drug: Nivolumab; Drug: Nivolumab Sponsors: The Netherlands Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Melanoma; Lung Neoplasms; Head and Neck Neoplasms Interventions: Drug: KSQ-001EX; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: M.D. Anderson Cancer Center; KSQ Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
